{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Coria LM"],"funding":["NIAID NIH HHS"],"pagination":["844837"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8919065"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel <i>Brucella</i> spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and alum as adjuvants has a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus alum, AddaVax, or AddaS03. Antibodies induced with the formulation containing U-Omp19 and alum not only increased their neutralization capacity against the ancestral virus but also cross-neutralized alpha, lambda, and gamma variants with similar po"],"journal":["Frontiers in immunology"],"pubmed_title":["A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice."],"pmcid":["PMC8919065"],"funding_grant_id":["R01 AI153433"],"pubmed_authors":["Chemes LB","Pueblas Castro C","Pasquevich KA","Salvatori M","Auguste AJ","Alvarez DE","Darriba ML","Saposnik LM","Perez PS","Bruno LA","Mazzitelli I","Castro EF","Cassataro J","Coria LM","Stone WB","Alcain J","Varese A"],"additional_accession":[]},"is_claimable":false,"name":"A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.","description":"In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel <i>Brucella</i> spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and alum as adjuvants has a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus alum, AddaVax, or AddaS03. Antibodies induced with the formulation containing U-Omp19 and alum not only increased their neutralization capacity against the ancestral virus but also cross-neutralized alpha, lambda, and gamma variants with similar po","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-18T12:10:26.021Z","creation":"2025-04-06T21:49:25.985Z"},"accession":"S-EPMC8919065","cross_references":{"pubmed":["35296091"],"doi":["10.3389/fimmu.2022.844837"]}}